Author

Lingge Feng

Observed name: LINGGE FENG

Observed institution: Hua Medicine (China)

ORCID: 0000-0001-8540-5960

Observed ORCID: 0000-0001-8540-5960

OpenAlex ID: A5058684135

A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

2023 · Li Chen, Jiayi Zhang, et al. · Nature Communications · 27

PDF

117-LB: Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP-1 Release in T2D Patients and Is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta-Cell Function

2021 · LI CHEN, JIAYI ZHANG, et al. · Diabetes · 11

Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels

2023 · Rui Sun, Yanli Duan, et al. · Diabetes Therapy · 9

PDF

Improvement of early‐phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study

2023 · Lingge Feng, Chunxiang Chen, et al. · Diabetes Obesity and Metabolism · 4

PDF

Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus

2023 · Kun Wang, Lingge Feng, et al. · Clinical Pharmacokinetics · 4

PDF

117-LB: Glucokinase Activator Restores Glucose Sensitivity and Early-Phase Insulin Secretion in T2DM Patient—A Post Hoc Analysis of Dorzagliatin

2022 · LINGGE FENG, QUANLE GUO, et al. · Diabetes · 4

Dorzagliatin shows potential in preventing cognitive impairment in diabetes: evidence from Mendelian randomization analysis and animal study

2026 · Jiangxia Ni, Ke Wang, et al. · Frontiers in Endocrinology · 1

PDF

128-LB: Accessing Glucose Fluctuation—The Role of FPG, PPG, and HbA1c

2023 · JIANHUA MA, XIAOFEI SU, et al. · Diabetes · 1

1322-OR: Synergistic Effects of Dorzagliatin and Orforglipron on Glycemic Control and Adiposity in DIO Mice

2026 · LINGGE FENG, XIAOBO GAO, et al. · Diabetes

3049-LB: Synergistic Effects of Dorzagliatin and Chiglitazar on Metabolic in DIO mice with MASLD

2026 · XIAOBO GAO, LINGGE FENG, et al. · Diabetes

A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial

2026 · Huan Liu, Yuanhui Zhang, et al. · Nature Communications

PDF

893-P: Long-Term Administration of Dorzagliatin Combined with Sitagliptin for the Management of Glucose Homeostasis in High-Fat Diet–Induced Obesity Mice

2025 · DONGNA HAN, SHI MENG, et al. · Diabetes

A phase I open-label sequential clinical trial and population oral minimal model to study pharmacodynamic interactions of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity

2025 · Huan Liu, Yuanhui Zhang, et al. · American Conference on Pharmacometrics (ACoP)

Front Cover

2024 · Lingge Feng, Chunxiang Chen, et al. · Diabetes Obesity and Metabolism

PDF

Author response for "Improvement of early‐phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study"

2023 · Lingge Feng, Chunxiang Chen, et al. · Publons reviews and discussion

96-LB: Dorzagliatin Improves Beta-Cell Function in Patients with Type 2 Diabetes

2023 · YUANHUI ZHANG, LINGGE FENG, et al. · Diabetes

247-LB: Link between Hyperglycemia and Cognitive Deficits in T2DM Animal Model

2023 · LI CHEN, JIANGXIA NI, et al. · Diabetes

Dorzagliatin improves glucose-stimulated GLP-1 secretion in T2D and is synergistic with sitagliptin in glycemic control

2022 · Li Chen, Jiayi Zhang, et al. · Research Square

PDF

1158-P: Type 2 Diabetes Patients Subtype Analysis: Unbiased Machine Learning for Future Personalized T2D Care

2019 · LI CHEN, LINGGE FENG, et al. · Diabetes

Works count: 19

Citation count: 61

H-index: 4

I10-index: 2